SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Phase 2SCI-110Positive

AI Analysis

Summary

SciSparc's subsidiary NeuroThera Labs announced the initiation of a Phase IIb clinical trial for SCI-110, a cannabinoid-based treatment for adult Tourette Syndrome, at Hannover Medical School in Germany.

Clinical Trial Data

Phase

IIb

Outcome Details

Phase IIb clinical trial site initiated at Hannover Medical School in Germany

Importance:5/10

Sentiment:

0.50

Phase IIbTourette SyndromecannabinoidCNS disordersclinical trial initiationGermany

Related Companies

$SPRC $NTLX

Read the original article

Published by GlobeNewswire Pharma on July 15, 2026 12:41 PM

Read Original